Journal of Enzyme Inhibition and Medicinal Chemistry · 2012 · 36 citations · 33 references
MedicineMedicinal ChemistryPharmacologyPain ManagementPain MedicineStructure-activity RelationshipsAnalgesiaAnalgesic PharmacologyPharmacologic Pain TherapyStructure-activity Relationship AnalysisAmide HydrolysisAnalgesic Drug MechanismsCannabinoid AnalgesicsCyclooxygenase InhibitorsCyclooxygenase PathwaysCyclooxygenase-1 InhibitionPharmacologic Pain TreatmentPharmacological Pain Relief
A dual-action cyclooxygenase (COX)-fatty acid amide hydrolase (FAAH) inhibitor may have therapeutic usefulness as an analgesic, but a key issue is finding the right balance of inhibitory effects. This can be done by the design of compounds exhibiting different FAAH/COX-inhibitory potencies. In the present study, eight ibuprofen analogues were investigated. Ibuprofen (1), 2-(4-Isobutylphenyl)-N-(2-(3-methylpyridin-2-ylamino)-2-oxoethyl)propanamide (9) and N-(3-methylpyridin-2-yl)-2-(4'-isobutylphenyl)propionamide (2) inhibited FAAH with IC(50) values of 134, 3.6 and 0.52 µM respectively. The corresponding values for COX-1 were ~29, ~50 and ~60 µM, respectively. Using arachidonic acid as substrate, the compounds were weak inhibitors of COX-2. However, when anandamide was used as COX-2 substrate, potency increased, with approximate IC(50) values of ~6, ~10 and ~19 µM, respectively. Compound 2 was confirmed to be active in vivo in a murine model of visceral nociception, but the effects of the compound were not blocked by CB receptor antagonists.
33
Elizabeth A. Meade, William L. Smith, David L. DeWitt · Journal of Biological Chemistry · 1993 · 1.3K citations · Full text
Medicine, Biochemistry, Pharmacology +15
Edward D. Högestätt, Bo Jönsson, Anna Ermund et al. · Journal of Biological Chemistry · 2005 · 448 citations · Full text
Medicine, Neuroscience, Pharmacology +15